Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Gongdong Medical Technology Co.,Ltd. (605369.SS)
CNY17.28
+0.15 (+0.88%)
CN SHH Healthcare Medical - Instruments & Supplies
Address
No.10 Beiyuan Avenue
Taizhou, CN
Taizhou, CN
CEO
Weifeng Zhong
Website
chinagongdong.com
IPO
2020-09-16
ISIN CNE1000042X4
Description
Zhejiang Gongdong Medical Technology Co.,Ltd. is a Chinese company specializing in the research, development, manufacturing, and distribution of a diverse array of medical devices and diagnostic consumables. Its comprehensive product portfolio includes laboratory disposables, advanced vacuum blood and specimen collection systems, medical patient care items, pharmaceutical packaging solutions, and custom mold fabrication services. The company was established in 1985 and is headquartered in Taizhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.28
+0.15 (+0.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.56
Float Shares
68.42M
Free Float %
31.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.16% | -7.84% | -6.95% | -2.96% | -3.58% | -1.77% | -2.29% | -34.98% | -61.57% | -21.20% | -21.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.28
DCF (Unlevered)
14.01
-18.9%
DCF (Levered)
17.80
+3.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.89
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+1.8% Q1'26: +9.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-70.5% Q1'26: +25.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+7.4% Q1'26: +3.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+6.0% Q1'26: +13.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.6% Q1'26: +10.6% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1.6% Q1'26: -5.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.89× ★ Q1'26: 1.46× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.19B
est: 1.10B (+8.4%)
|
1.47B
est: 1.57B (-6.2%)
|
975.08M
est: 1.07B (-8.9%)
|
1.12B
est: 1.21B (-7.5%)
|
1.14B
est: 1.16B (-2.4%)
|
1.34B
1.25B – 1.43B
+15.1% YoY
|
1.52B
1.43B – 1.61B
+13.4% YoY
|
| EBITDA |
382.52M
est: 309.83M (+23.5%)
|
411.36M
est: 440.29M (-6.6%)
|
204.89M
est: 258.02M (-20.6%)
|
274.26M
est: 290.41M (-5.6%)
|
168.75M
est: 280.53M (-39.8%)
|
322.95M
300.83M – 345.06M
+15.1% YoY
|
366.09M
343.58M – 388.59M
+13.4% YoY
|
| EBIT |
361.00M
est: 257.11M (+40.4%)
|
370.70M
est: 365.37M (+1.5%)
|
120.91M
est: 195.08M (-38.0%)
|
191.94M
est: 219.57M (-12.6%)
|
68.49M
est: 212.10M (-67.7%)
|
244.17M
227.45M – 260.89M
+15.1% YoY
|
276.79M
259.77M – 293.80M
+13.4% YoY
|
| Net Income |
310.99M
est: 225.35M (+38.0%)
|
326.04M
est: 289.22M (+12.7%)
|
109.13M
est: 204.70M (-46.7%)
|
171.63M
est: 204.75M (-16.2%)
|
51.51M
est: 109.73M (-53.1%)
|
172.50M
140.94M – 172.58M
+57.2% YoY
|
202.00M
187.34M – 206.80M
+17.1% YoY
|
| SGA |
120.43M
est: 74.30M (+62.1%)
|
162.48M
est: 105.59M (+53.9%)
|
148.20M
est: 116.59M (+27.1%)
|
141.21M
est: 131.23M (+7.6%)
|
61.82M
est: 126.76M (-51.2%)
|
145.93M
135.94M – 155.92M
+15.1% YoY
|
165.42M
155.25M – 175.59M
+13.4% YoY
|
| EPS |
1.41
est: 1.43 (-1.5%)
|
1.48
est: 1.84 (-19.4%)
|
0.49
est: 0.91 (-46.4%)
|
0.78
est: 0.91 (-14.7%)
|
0.23
est: 0.49 (-53.1%)
|
0.70
0.63 – 0.77
+42.9% YoY
|
0.88
0.84 – 0.92
+25.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
138.77M
OE per share TTM
0.65
Owner's Yield
3.55%
Maintenance CapEx ratio
89.76%
Maint CapEx / Avg PPE
48.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 143.3K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 37.2K | 0.29% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.9K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.1K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 547.3K | 0.06% |
| 6 | Vanguard Total World Stock ETF VT | 0.00% | 212.4K | 0.06% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 8.4K | 0.10% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 621.2K | 0.05% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 879.52 | 0.22% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.6K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
40.5K
Shares Outstanding
218.74M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ling Ting Mu | Secretary | — | female |
| Shangxiao Lai | Deputy General Manager | — | male |
| Weifeng Zhong | GM & Director | — | male |
| Yong Zhu | Financial Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 605369.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
